Missionirnewsbreaks Nanoviricides (NYSE American: NNVC) Prices $2 Million Registered Direct Offering

(MENAFN- Investor Brand Network) NanoViricides, Inc. (NYSE American: NNVC) announced a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds through the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants will carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions.

To view the full press release, visit

About NanoViricides

NanoViricides, Inc., is a publicly traded company (NYSE American: NNVC) (the“Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape. Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an“Orphan Drug Designation” (ODD) by the US FDA Office of Orphan Products Development (OOPD). This could provide 7 years market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is a revolutionary antiviral that we believe will be the drug offered at“first visit” when the patient presents to a doctor with any respiratory viral illness. NV-387 was also found to be highly effective in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.

NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company's newsroom at

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: imer, Texas

512.354.7000 Office
href="/cdn-cgi/l/email-protection#a0e5c4c9d4cfd2e0edc9d3d3c9cfcee9f28ec3cfcd" target="_blank" rel="noreferrer noopener">[email protected]

MissionIR is powered by IBN

MENAFN15052026000224011066ID1111122493